Do analysts prefer ARTL or CABR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ARTL or CABR?

Caring Brands is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A Caring Brands N/A N/A -$6.28M -$0.74 N/A

Is ARTL or CABR more profitable?

Artelo Biosciences' return on equity of -518.27% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% Caring Brands N/A -1,153.12% -322.63%

Does the media prefer ARTL or CABR?

In the previous week, Caring Brands had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Caring Brands and 2 mentions for Artelo Biosciences. Caring Brands' average media sentiment score of 1.02 beat Artelo Biosciences' score of 0.93 indicating that Caring Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caring Brands 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ASBP or ARTL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer ASBP or ARTL?

In the previous week, Aspire Biopharma had 4 more articles in the media than Artelo Biosciences. MarketBeat recorded 6 mentions for Aspire Biopharma and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Aspire Biopharma's score of 0.75 indicating that Artelo Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FNCH or ARTL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, FNCH or ARTL?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A

Is FNCH or ARTL more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Artelo Biosciences N/A -518.27% -194.29%

Do analysts prefer ARTL or KPRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARTL or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% Kiora Pharmaceuticals N/A -63.38% -44.33%

Does the media favor ARTL or KPRX?

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Kiora Pharmaceuticals' score of 0.47 indicating that Artelo Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MDCX or ARTL?

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 5,549.72%. Given Medicus Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Medicus Pharma is more favorable than Artelo Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, MDCX or ARTL?

Medicus Pharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.46 N/A Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A

Is MDCX or ARTL more profitable?

Artelo Biosciences' return on equity of -518.27% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% Artelo Biosciences N/A -518.27% -194.29%

Does the media refer more to MDCX or ARTL?

In the previous week, Medicus Pharma had 13 more articles in the media than Artelo Biosciences. MarketBeat recorded 15 mentions for Medicus Pharma and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Medicus Pharma's score of 0.60 indicating that Artelo Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Artelo Biosciences (ARTL) Competitors

$4.87 -0.56 (-10.31%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$5.06 +0.19 (+3.80%)

As of 05:46 AM Eastern

Compare

ARTL vs. CABR, ASBP, FNCH, KPRX, and MDCX

Should you buy Artelo Biosciences stock or one of its competitors? Artelo Biosciences's main competitors and comparable companies include Caring Brands (CABR), Aspire Biopharma (ASBP), Finch Therapeutics Group (FNCH), Kiora Pharmaceuticals (KPRX), and Medicus Pharma (MDCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Artelo Biosciences compare to Caring Brands?

Artelo Biosciences (NASDAQ:ARTL) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Caring Brands had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Caring Brands and 2 mentions for Artelo Biosciences. Caring Brands' average media sentiment score of 1.02 beat Artelo Biosciences' score of 0.93 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caring Brands	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.9% of Artelo Biosciences shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by insiders. Comparatively, 14.6% of Caring Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Artelo Biosciences' return on equity of -518.27% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Caring Brands	N/A	-1,153.12%	-322.63%

Caring Brands is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A

Summary

Artelo Biosciences and Caring Brands tied by winning 5 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and Artelo Biosciences (NASDAQ:ARTL) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Artelo Biosciences has lower revenue, but higher earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A

Artelo Biosciences has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Artelo Biosciences	N/A	-518.27%	-194.29%

In the previous week, Aspire Biopharma had 4 more articles in the media than Artelo Biosciences. MarketBeat recorded 6 mentions for Aspire Biopharma and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Aspire Biopharma's score of 0.75 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

Summary

Aspire Biopharma beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Artelo Biosciences	N/A	-518.27%	-194.29%

In the previous week, Artelo Biosciences had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Artelo Biosciences and 0 mentions for Finch Therapeutics Group. Artelo Biosciences' average media sentiment score of 0.93 beat Finch Therapeutics Group's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Artelo Biosciences	Positive

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Finch Therapeutics Group beats Artelo Biosciences on 6 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to Kiora Pharmaceuticals?

Artelo Biosciences (NASDAQ:ARTL) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals has higher revenue and earnings than Artelo Biosciences. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A

Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -63.38% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Kiora Pharmaceuticals' score of 0.47 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kiora Pharmaceuticals beats Artelo Biosciences on 7 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 5,549.72%. Given Medicus Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Medicus Pharma is more favorable than Artelo Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

0.9% of Artelo Biosciences shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

Artelo Biosciences' return on equity of -518.27% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Artelo Biosciences	N/A	-518.27%	-194.29%

In the previous week, Medicus Pharma had 13 more articles in the media than Artelo Biosciences. MarketBeat recorded 15 mentions for Medicus Pharma and 2 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.93 beat Medicus Pharma's score of 0.60 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	6 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medicus Pharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A

Summary

Medicus Pharma beats Artelo Biosciences on 7 of the 13 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.97M	$12.45B	$7.16B	$14.30B
Dividend Yield	N/A	2.64%	2.57%	11.70%
P/E Ratio	-0.03	794.71	273.30	25.37
Price / Sales	N/A	756.38	650.46	87.69
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-0.29	10.43	10.48	6.24
Net Income	-$12.88M	$2.84B	$3.49B	$358.08M
7 Day Performance	-21.32%	-2.39%	-1.09%	-0.70%
1 Month Performance	-31.52%	1.37%	0.63%	-2.76%
1 Year Performance	-96.56%	4.50%	20.22%	6.72%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	0.5851 of 5 stars	$4.87 -10.3%	N/A	-96.6%	$2.97M	N/A	N/A	5	Gap Down
CABR Caring Brands	0.4577 of 5 stars	$1.11 -11.9%	N/A	N/A	$13.06M	N/A	N/A	4	Short Interest Increase
ASBP Aspire Biopharma	0.7854 of 5 stars	$8.85 -0.2%	N/A	-98.3%	$12.44M	$10K	N/A	N/A	Short Interest Decrease
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
KPRX Kiora Pharmaceuticals	0.6659 of 5 stars	$2.51 -1.6%	N/A	+0.4%	$11.28M	$16.02M	N/A	10	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. CABR, ASBP, FNCH, KPRX, and MDCX

How does Artelo Biosciences compare to Caring Brands?

Summary

How does Artelo Biosciences compare to Aspire Biopharma?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Summary

How does Artelo Biosciences compare to Kiora Pharmaceuticals?

Summary

How does Artelo Biosciences compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. CABR, ASBP, FNCH, KPRX, and MDCX

How does Artelo Biosciences compare to Caring Brands?

Do analysts prefer ARTL or CABR?

Does the media prefer ARTL or CABR?

Do insiders & institutionals believe in ARTL or CABR?

Is ARTL or CABR more profitable?

Which has higher earnings & valuation, ARTL or CABR?

Summary

How does Artelo Biosciences compare to Aspire Biopharma?

Do analysts recommend ASBP or ARTL?

Do insiders and institutionals believe in ASBP or ARTL?

Which has higher valuation and earnings, ASBP or ARTL?

Is ASBP or ARTL more profitable?

Does the media prefer ASBP or ARTL?

Which has more risk & volatility, ASBP or ARTL?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Which has more risk & volatility, FNCH or ARTL?

Is FNCH or ARTL more profitable?

Does the media refer more to FNCH or ARTL?

Which has preferable valuation and earnings, FNCH or ARTL?

Do insiders and institutionals have more ownership in FNCH or ARTL?

Do analysts recommend FNCH or ARTL?

Summary

How does Artelo Biosciences compare to Kiora Pharmaceuticals?

Do institutionals & insiders believe in ARTL or KPRX?

Do analysts prefer ARTL or KPRX?

Which has better earnings and valuation, ARTL or KPRX?

Which has more volatility & risk, ARTL or KPRX?

Is ARTL or KPRX more profitable?

Does the media favor ARTL or KPRX?

Summary

How does Artelo Biosciences compare to Medicus Pharma?

Do analysts recommend MDCX or ARTL?

Do insiders and institutionals have more ownership in MDCX or ARTL?

Which has more volatility & risk, MDCX or ARTL?

Is MDCX or ARTL more profitable?

Does the media refer more to MDCX or ARTL?

Which has stronger valuation and earnings, MDCX or ARTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools